Astemizole reduces blood-retinal barrier leakage in experimental diabetes
| Autor: | Manuel J. Campos, Theodore M. Hollis, Cecil Butler, Thomas W. Gardner, Howard W. Sill |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Blood–retinal barrier Histamine H1 receptor Diabetes Mellitus Experimental Capillary Permeability chemistry.chemical_compound Endocrinology Reference Values Internal medicine Diabetes mellitus Internal Medicine medicine Animals Rats Wistar Serum Albumin Diabetic Retinopathy business.industry Body Weight Albumin Antagonist Retinal Vessels Astemizole Streptozotocin medicine.disease Rats Vitreous Body medicine.anatomical_structure chemistry business Histamine Fluorescein-5-isothiocyanate medicine.drug |
| Zdroj: | Journal of diabetes and its complications. 6(4) |
| ISSN: | 1056-8727 |
| Popis: | We examined the potential of astemizole, a histamine H1-receptor antagonist that does not cross the blood-brain barrier, to reverse blood-retinal barrier leakage to albumin in streptozotocin diabetic rats. Four groups of nondiabetic and four groups of diabetic rats received vehicle or astemizole at dosages of 5, 10, or 20 mg/kg body weight for days 22-28 of a 28-day holding period. There were no significant differences in nondiabetic plasma-vitreous albumin ratios between animals receiving vehicle or any of the three astemizole dosages. Only diabetic rats receiving vehicle showed a significant (p < 0.05) 100% increase in the plasma-vitreous albumin ratio over their nondiabetic counterparts. Diabetic rats receiving either 5, 10, or 20 mg/kg astemizole exhibited total normalization of vitreous albumin accumulation, despite persistence of diabetes. These data indicate that astemizole, an H1-receptor antagonist that does not cross the blood-retinal barrier, is effective in reversing blood-retinal barrier leakage of albumin in experimental diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|